It affects an estimated one in three adults globally. It progresses silently, often without symptoms, until the liver is scarred beyond repair. And until now, there has been no widely available pharmaceutical treatment for its early stages.
Metabolic dysfunction-associated steatotic liver disease — what most people still call fatty liver disease — may have just met its match. Not from a billion-dollar experimental drug, but from two medications that already sit on pharmacy shelves around the world.
The Combination
Researchers at the University of Barcelona, working with collaborators at the Institute of Biomedicine, CIBER, and Uppsala University in Sweden, found that combining pemafibrate and telmisartan dramatically reduced liver fat in animal models of the disease.
Pemafibrate is a lipid-lowering agent. Telmisartan is a blood pressure medication. Neither was designed to treat liver disease. But used together, they not only improved liver health markers but also reduced the associated cardiovascular risks that make fatty liver disease so dangerous.
The study, led by Professor Marta Alegret of Barcelona’s Faculty of Pharmacy and Food Sciences, was published in April 2026.
Why Repurposing Matters
Developing a new drug from scratch takes a decade or more and costs billions. Repurposing existing medications — drugs whose safety profiles are already established through years of clinical use — offers a dramatically faster and cheaper path to treatment.
Both pemafibrate and telmisartan have known side effect profiles, established dosing guidelines, and existing manufacturing infrastructure. If the combination proves effective in human trials, it could reach patients far sooner than any novel compound currently in development.
The Silent Epidemic
Fatty liver disease is often called the silent epidemic for good reason. Most people who have it do not know. It produces no pain, no obvious symptoms, and is frequently discovered incidentally during imaging for unrelated conditions. By the time symptoms appear — fatigue, abdominal swelling, jaundice — the liver may already be severely damaged.
The disease is driven by the same forces reshaping global health: processed diets, sedentary lifestyles, rising obesity rates, and metabolic syndrome. Its prevalence has surged in lockstep with these trends, yet treatment options have lagged far behind.
With this combination approach, the gap between a disease that affects billions and a treatment that could help them may have just narrowed considerably — using tools that were already in the medicine cabinet.
